Definium Therapeutics, Inc. (DFTX) key performance indicators and operating metrics (4 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Emerge Study Expected Enrollment Major Depressive Disorder | 149.00 | FY2026-Q1 |
| Panorama Study Expected Enrollment Generalized Anxiety Disorder | 200.00 | FY2026-Q1 |
| Voyage Study Expected Enrollment Generalized Anxiety Disorder | 214.00 | FY2026-Q1 |
| Ascend Study Expected Enrollment Major Depressive Disorder | 175.00 | FY2026-Q1 |
Back to DFTX overview · DFTX earnings · DFTX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.